Neumora Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: South San Francisco CA United States (2013)

Organization Overview

First Clinical Trial
2013
NCT01263236
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

BlackThorn Therapeutics | BlackThorn Therapeutics, Inc. | BlackThorn Therapeutics, Inc. (Sponsor) | Neumora Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

btrx-335140 (5 trials)

Drugs in Phase 2 Trials (2)

btrx-246040 (2 trials)

ly2940094 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcoholism (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Motor Disorders (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 3